Krystal Biotech, Inc. (4KB.SG)

Compare

152.15

+2.00

+(1.33%)

At close: January 31 at 9:34:10 PM GMT+1

Is the Options Market Predicting a Spike in Krystal Biotech (KRYS) Stock?

Investors need to pay close attention to Krystal Biotech (KRYS) stock based on the movements in the options market lately.

Zacks 8 days ago

KRYS
US Growth Companies With High Insider Ownership In January 2025

As the U.S. markets continue to rally, buoyed by President Trump's recent executive actions and a positive economic outlook, investors are increasingly focused on growth companies with solid fundamentals. In this environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and strategic direction.

Simply Wall St. 10 days ago

KRYS

PAY

VNET
High Growth Tech Stocks to Watch in January 2025

Over the last week, the United States market saw a 3.1% increase, contributing to a 24% climb over the past year, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying high-growth tech stocks that align with these optimistic projections can be crucial for investors looking to capitalize on emerging opportunities in this dynamic sector.

Simply Wall St. 10 days ago

KRYS

LEGN

SLNO
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisi

GlobeNewswire 18 days ago

KRYS
3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth

As the U.S. stock market inches higher in a holiday-shortened session, with indices like the Nasdaq Composite and S&P 500 posting modest gains, investors are keeping a close eye on growth stocks that demonstrate robust potential amid fluctuating economic conditions. In this context, companies with high insider ownership can be particularly appealing, as significant insider stakes often signal confidence in the company's future prospects and alignment of interests between management and...

Simply Wall St. last month

KRYS

AMRC

HROW
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

It is hard to get excited after looking at Krystal Biotech's (NASDAQ:KRYS) recent performance, when its stock has...

Simply Wall St. last month

KRYS
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.

Zacks last month

KRYS

CSTL
Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy Activity

Krystal Biotech (KRYS) said Wednesday that preliminary results from its Kyanite-1 clinical trial sho

PREMIUM
MT Newswires last month

KRYS
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, an

GlobeNewswire last month

KRYS
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.

Zacks last month

KRYS
Krystal Biotech announces initial update for KB408, KB407

Krystal Biotech (KRYS) clinical data updates for both KB408 and KB407, the Company’s clinical-stage, inhaled genetic medicine programs in Phase 1 for the treatment of rare respiratory diseases. Today’s updates include molecular data from multiple patients demonstrating SERPINA1 delivery and alpha-1 antitrypsin, AAT, expression within the respiratory tract following KB408 administration as well as safety and tolerability data for both KB407 and KB408 that, taken together, highlight the potential

TipRanks last month

KRYS
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

PRTA

KRYS
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels

Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and well tolerated at all dosing regimens evaluated to date Conditional sanctioning of the KB407 Phase 1 CF Study CORAL-1 protocol by CFF TDN Investor call and webcast to be held December 12 at 8:30 am ET to discuss data update PITTSBURGH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company

GlobeNewswire last month

KRYS
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company’s Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC

GlobeNewswire last month

KRYS
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

CRSP

KRYS
Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

KRYS

INSM
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 2 months ago

KRYS
Krystal Biotech to Present at Upcoming Investor Conferences

PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences: Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET7th Annual Evercore HealthCONx Conference on December 4, 2024 in

GlobeNewswire 2 months ago

KRYS
High Growth Tech Stocks Featuring Three Prominent US Companies

Over the last 7 days, the United States market has risen 5.7%, contributing to a remarkable 37% increase over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable market conditions.

Simply Wall St. 2 months ago

NBIX

KRYS

RYTM
Krystal Biotech to Present at Stifel 2024 Healthcare Conference

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference on November 18, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:55 am ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 10:

GlobeNewswire 2 months ago

KRYS

Performance Overview

Return	4KB.SG	S&P 500
YTD	+0.56%	+2.26%
1-Year	+39.59%	+22.65%
3-Year	+233.66%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Krystal Biotech, Inc. (4KB.SG)

Is the Options Market Predicting a Spike in Krystal Biotech (KRYS) Stock?

US Growth Companies With High Insider Ownership In January 2025

High Growth Tech Stocks to Watch in January 2025

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth

Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy Activity

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Krystal Biotech announces initial update for KB408, KB407

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels

Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?

Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Krystal Biotech to Present at Upcoming Investor Conferences

High Growth Tech Stocks Featuring Three Prominent US Companies

Krystal Biotech to Present at Stifel 2024 Healthcare Conference

Performance Overview